63 related articles for article (PubMed ID: 9842268)
1. [Minimum inhibitory concentration of amphotericin B in yeasts of medical interest].
Fernández Andreu CM; González Miranda M; Illnait Zaragozí MT; Martínez Machín G
Rev Cubana Med Trop; 1998; 50(1):48-53. PubMed ID: 9842268
[TBL] [Abstract][Full Text] [Related]
2. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
3. Susceptibilities to amphotericin B and fluconazole of Candida species in TSARY 2002.
Yang YL; Li SY; Cheng HH; Lo HJ;
Diagn Microbiol Infect Dis; 2005 Mar; 51(3):179-83. PubMed ID: 15766603
[TBL] [Abstract][Full Text] [Related]
4. Survey of amphotericin B susceptibility of Candida clinical isolates determined by Etest.
Chiu YS; Chang SC; Hsueh PR; Wang JL; Sun HY; Chen YC
J Microbiol Immunol Infect; 2006 Aug; 39(4):335-41. PubMed ID: 16926981
[TBL] [Abstract][Full Text] [Related]
5. Susceptibilities to amphotericin B and fluconazole of Candida species in Taiwan Surveillance of Antimicrobial Resistance of Yeasts 2006.
Yang YL; Wang AH; Wang CW; Cheng WT; Li SY; Lo HJ;
Diagn Microbiol Infect Dis; 2008 Jun; 61(2):175-80. PubMed ID: 18304773
[TBL] [Abstract][Full Text] [Related]
6. [In vitro sensitivity of Histoplasma capsulatum var. capsulatum to amphotericin B, ketoconazole, itroconazole and fluconazole].
Andreu CM; León AM; Medina YE; Machín GM; Lancha MR; Zaragozí MT
Rev Cubana Med Trop; 2003; 55(2):76-82. PubMed ID: 15849960
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of a dried commercially prepared microdilution panel for antifungal susceptibility testing of five antifungal agents against Candida spp. and Cryptococcus neoformans.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
Diagn Microbiol Infect Dis; 2004 Oct; 50(2):113-7. PubMed ID: 15474320
[TBL] [Abstract][Full Text] [Related]
8. Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies.
Johnson E; Espinel-Ingroff A; Szekely A; Hockey H; Troke P
Int J Antimicrob Agents; 2008 Dec; 32(6):511-4. PubMed ID: 18790613
[TBL] [Abstract][Full Text] [Related]
9. Antifungal drug combinations for Cryptococcus neoformans and Prototheca spp.
Srimuang S; Prariyachatigul C; Chaiprasert A; Rungsipanuratn W; Tanphaichitra D
J Med Assoc Thai; 2000 Jan; 83(1):57-60. PubMed ID: 10710870
[TBL] [Abstract][Full Text] [Related]
10. [Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans].
Fernández Andreu CM; Pimentel Turino T; Martínez Machín G; González Miranda M
Rev Cubana Med Trop; 1999; 51(1):55-7. PubMed ID: 10887558
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period.
Kucukates E; Erturan Z; Susever S; Yegenoglu Y
APMIS; 2005 Apr; 113(4):278-83. PubMed ID: 15865609
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study.
Mallié M; Bastide JM; Blancard A; Bonnin A; Bretagne S; Cambon M; Chandenier J; Chauveau V; Couprie B; Datry A; Feuilhade M; Grillot R; Guiguen C; Lavarde V; Letscher V; Linas MD; Michel A; Morin O; Paugam A; Piens MA; Raberin H; Tissot E; Toubas D; Wade A
Int J Antimicrob Agents; 2005 Apr; 25(4):321-8. PubMed ID: 15784312
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of 2-cyclohexylidenhydrazo-4-phenyl-thiazole compared with those of amphotericin B and fluconazole against clinical isolates of Candida spp. and fluconazole-resistant Candida albicans.
De Logu A; Saddi M; Cardia MC; Borgna R; Sanna C; Saddi B; Maccioni E
J Antimicrob Chemother; 2005 May; 55(5):692-8. PubMed ID: 15772140
[TBL] [Abstract][Full Text] [Related]
14. [Biofilm production and antifungal susceptibility patterns of Candida species].
Yücesoy M; Karaman M
Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
[TBL] [Abstract][Full Text] [Related]
15. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
Favel A; Michel-Nguyen A; Datry A; Challier S; Leclerc F; Chastin C; Fallague K; Regli P
J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
[TBL] [Abstract][Full Text] [Related]
16. [Determination of in vitro susceptibility of Candida species to amphotericin B by E-test and previously proposed MIC breakpoints on two different media].
Alp S; Sancak B; Arikan S
Mikrobiyol Bul; 2008 Apr; 42(2):293-300. PubMed ID: 18697427
[TBL] [Abstract][Full Text] [Related]
17. [Multicenter study of fungemia due to yeasts in Argentina].
Rodero L; Davel G; Soria M; Vivot W; Córdoba S; Canteros CE; Saporiti A;
Rev Argent Microbiol; 2005; 37(4):189-95. PubMed ID: 16502638
[TBL] [Abstract][Full Text] [Related]
18. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media].
Tapia C; León E; Palavecino E
Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079
[TBL] [Abstract][Full Text] [Related]
19. The trend of susceptibilities to amphotericin B and fluconazole of Candida species from 1999 to 2002 in Taiwan.
Yang YL; Li SY; Cheng HH; Lo HJ;
BMC Infect Dis; 2005 Nov; 5():99. PubMed ID: 16266438
[TBL] [Abstract][Full Text] [Related]
20. [Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration].
Alvarado D; Díaz MC; Silva V
Rev Med Chil; 2002 Apr; 130(4):416-23. PubMed ID: 12090107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
